PMAM
ADVM

Picton Mahoney Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Picton Mahoney Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-123,743
Closed -$850K – 842
2024
Q2 		$850K Sell
123,743
-223
-0.2% -$2.07K 0.03% 240
2024
Q1 		$1.75M Buy
+123,966
New +$1.89M 0.05% 212

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Picton Mahoney Asset Management's ADVM Position: Q3 2024 in Review

Picton Mahoney Asset Management sold out of Adverum Biotechnologies (ADVM) in Q3 2024, closing a stake of 123,743 shares — an estimated $850K sold.

Picton Mahoney Asset Management first reported a position in ADVM in Q1 2024 and held it in 2 quarters. The position peaked at $1.75M in Q1 2024. 77 funds tracked by Wall St. Rank hold ADVM as of Q3 2024.

  • Picton Mahoney Asset Management reported no remaining Adverum Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 123,743 Adverum Biotechnologies shares in Q3 2024, an estimated $850K.
  • Picton Mahoney Asset Management first reported a position in Adverum Biotechnologies in Q1 2024 and held it in 2 quarters.
  • Picton Mahoney Asset Management's Adverum Biotechnologies position peaked at $1.75M in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2024.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.